Cargando…

Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results

IMPORTANCE: Interpreting randomized clinical trials (RCTs) and their clinical relevance is challenging when P values are either marginally above or below the P = .05 threshold. OBJECTIVE: To use the concept of reverse fragility index (RFI) to provide a measure of confidence in the neutrality of RCT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Muhammad Shahzeb, Fonarow, Gregg C., Friede, Tim, Lateef, Noman, Khan, Safi U., Anker, Stefan D., Harrell, Frank E., Butler, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407075/ https://www.ncbi.nlm.nih.gov/pubmed/32756927 http://dx.doi.org/10.1001/jamanetworkopen.2020.12469

Ejemplares similares

Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2021)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Evidence that nonsignificant results are sometimes preferred: Reverse P-hacking or selective reporting?
por: Chuard, Pierre J. C., et al.
Publicado: (2019)

Cardiovascular implications of COVID-19 versus influenza infection: a review
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Identifying spin bias of nonsignificant findings in biomedical studies
por: O’Leary, Renée, et al.
Publicado: (2023)

Lessons Learned From Nonsignificant Findings in Exercise With Individuals With Dementia
por: Dawson, Nicole, et al.
Publicado: (2020)

Correction: Identifying spin bias of nonsignificant findings in biomedical studies
por: O’Leary, Renée, et al.
Publicado: (2023)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Research on maize canopy center recognition based on nonsignificant color difference segmentation
por: Wang, Xiushan, et al.
Publicado: (2018)

Long-term clinical outcomes of patients with nonsignificant transplanted renal artery stenosis
por: Barteczko, Manoela Linhares Machado, et al.
Publicado: (2022)

Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials
por: Hamid, Arsalan, et al.
Publicado: (2022)

Nonsignificant P values cannot prove null hypothesis: Absence of evidence is not evidence of absence
por: Jaykaran,, et al.
Publicado: (2011)

Too True to be Bad: When Sets of Studies With Significant and Nonsignificant Findings Are Probably True
por: Lakens, Daniël, et al.
Publicado: (2017)

The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19
por: Itaya, Takahiro, et al.
Publicado: (2022)

The Kardashian Index of Cardiologists: Celebrities or Experts?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies: A Systematic Review
por: Khan, Safi U., et al.
Publicado: (2020)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Frailty and heart failure: State‐of‐the‐art review
por: Talha, Khawaja M., et al.
Publicado: (2023)

Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

The Robustness Index: Going Beyond Statistical Significance by Quantifying Fragility
por: Heston, Thomas F
Publicado: (2023)

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2021)

Recognizing the Significance of Outpatient Worsening Heart Failure
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

The statistical fragility of the management options for reverse shoulder arthroplasty: a systematic review of randomized control trial with fragility analysis
por: Doyle, Tom R., et al.
Publicado: (2023)

The need for increased pragmatism in cardiovascular clinical trials
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
por: Talha, Khawaja M., et al.
Publicado: (2022)

The Fragility Index in a Cohort of Pediatric Randomized Controlled Trials
por: Matics, Travis J., et al.
Publicado: (2017)

Long-Term Fragility of Y Chromosomes Is Dominated by Short-Term Resolution of Sexual Antagonism
por: Blackmon, Heath, et al.
Publicado: (2017)

How Fragile Are the Results of a Trial? The Fragility Index
por: Dettori, Joseph R., et al.
Publicado: (2020)

Fragility index and fragility quotient in randomized clinical trials
por: Garcia, Marcos Vinicius Fernandes, et al.
Publicado: (2023)

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
por: Anker, Stefan D., et al.
Publicado: (2022)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Statistical Significance Versus Clinical Relevance: A Head-to-Head Comparison of the Fragility Index and Relative Risk Index
por: Heston, Thomas F
Publicado: (2023)

Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry
por: Arnold, Suzanne V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9297f640llqla91kv75nl4fd8f